Intertrade Co.,Ltd. Revises Earnings Forecast Down 12.6% on Segment Weakness

Intertrade Co.,Ltd. Revises Earnings Forecast Down 12.6% on Segment Weakness

Intertrade Co.,Ltd. (TSE:3747) has cut its full-year earnings forecast for the fiscal year ending September 2026, citing delays in business solution project deliveries and underperformance in its healthcare segment.

The company attributed the downward revision primarily to revenue shortfalls in its Business Solution Business and Healthcare Business segments, which are expected to miss initial targets. The Business Solution Business faces persistent delays in project completion due to extended sales cycles, with multiple deals unlikely to close before fiscal year-end. This pattern of order underperformance has become recurring, the company noted. Meanwhile, the Healthcare Business continues to struggle with low consumer awareness of its functional food products despite obtaining regulatory approval for functional ingredient claims. Additionally, Intertrade expects a JPY 133M investment loss from equity-method affiliates Digital Asset Markets and AndGo, which are experiencing business plan delays. These factors combine to drive ordinary income (keijo rieki)—a Japan-specific metric encompassing operating profit plus non-operating items—into a loss position of JPY 142M.

The sharp 70% decline in operating profit signals deteriorating core business profitability. Investors should monitor whether management implements structural reforms to address the chronic order fulfillment gaps in the Business Solution segment, as this operational challenge appears systemic rather than cyclical. The company’s ability to stabilize revenue recognition and improve project execution will be critical to restoring investor confidence.

Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.